Phenoconversion of drug-metabolizing enzymes and its mechanism during inflammatory conditions
10.13220/j.cnki.jipr.2015.05.001
- Author:
Xiao-Mei ZHUANG
1
Author Information
1. State Key Laboratory of Toxicology and Medical Countermeasures, Laboratory of Drug Metabolism and Pharmacokinetics, Institute of Pharmacology and Toxicology, Academy of Military Medical Sciences
- Publication Type:Journal Article
- Keywords:
Cytokine;
Drug-metabolizing enzymes;
Inflammation;
Phenoconversion
- From:
Journal of International Pharmaceutical Research
2015;42(5):541-550
- CountryChina
- Language:Chinese
-
Abstract:
Inflammatory conditions are associated with most diseases. Phenoconversion of drug-metabolizing enzymes (DME) leads to altered drug metabolism and disposition. It has profound impact on the pharmacotherapy of widely used clinically relevant medications in terms of safety and efficacy. More and more evidence has proved that elevated levels of proinflammatory cytokines may downregulate the expression and the activity of many Phase I and Phase “DME, which are involved in complex regulation mechanisms of drug disposition. The aim of this review is to present the recent findings in this area. Clinical practice based on personalized medicine according to DME phenotype with improved safety and efficiency can yield robust efficacy outcomes of drug treatment and has promising future prospects.
